Condition : Systemic Lupus Erythematosus (SLE)
Interventions : Drug: Placebo; Drug: Dapirolizumab pegol (DZP)
Sponsor : UCB Biopharma S.P.R.L.
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Fri, 17 Jun 2016 12:00:00 EDT
>>> Updated January 29, 2019 >>> study status changed from active, not recruiting to completed